KYMR (Kymera Therapeutics) Total Operating Expense: $406.75 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KYMR Kymera Therapeutics Inc KYMR
46 GF Score
Price $103.26
GF Value $24.30
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Kymera Therapeutics Total Operating Expense?

Kymera Therapeutics KYMR -3.18% 46 Total Operating Expense is $406.75 Mil as of Mar. 2026. GuruFocus rates KYMR with a GF Score™ of 46/100 and a GF Value™ of $24.30 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Kymera Therapeutics's Total Operating Expense for the three months ended in Mar. 2026 was $118.52 Mil. Kymera Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $406.75 Mil.

Kymera Therapeutics Total Operating Expense Related Terms

Kymera Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Kymera Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kymera Therapeutics Total Operating Expense Chart

Kymera Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 173.36 208.08 244.12 303.78 384.76

Kymera Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 96.53 96.03 91.43 100.77 118.52
KYMR
46GF Score
Kymera Therapeutics Inc KYMR
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kymera Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $406.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $406.75 Mil mean?
Kymera Therapeutics (KYMR) has a Total Operating Expense of $406.75 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Kymera Therapeutics and its competitors.
Is Kymera Therapeutics' Total Operating Expense too high?
Kymera Therapeutics' current Total Operating Expense is $406.75 Mil. Overall, Kymera Therapeutics has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kymera Therapeutics' Total Operating Expense compare to PRAX and SYRE?
Kymera Therapeutics' Total Operating Expense of $406.75 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Kymera Therapeutics and its competitors. Kymera Therapeutics's current Total Operating Expense is $406.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kymera Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Kymera Therapeutics (KYMR) is currently considered Significantly Overvalued. The stock's GF Value™ is $24.30, compared to a current price of $103.26 — trading 324.9% above its estimated fair value. The current Total Operating Expense is $406.75 Mil. Kymera Therapeutics' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Kymera Therapeutics (KYMR), the current Total Operating Expense is $406.75 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kymera Therapeutics (KYMR) Overvalued in 2026?

Based on GuruFocus' analysis, Kymera Therapeutics stock appears to be overvalued. The current stock price of $103.26 is trading 324.9% above its estimated GF Value™ of $24.30. GuruFocus considers Kymera Therapeutics to be Significantly Overvalued.

Key valuation signals for KYMR:

  • Total Operating Expense: $406.75 Mil
  • GF Value™: $24.30 vs. price of $103.26 (324.9% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the KYMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kymera Therapeutics Business Description

Address 500 North Beacon Street, 4th Floor, Watertown, MA, USA, 02472
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
46GF Score

Get the complete analysis for KYMR

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$103.26
Price
$24.30
GF Value